Evidence map›Paper›PMID 39058955›Full record

ArticleArchivos de cardiologia de Mexico2024

[COVID-19 in patients with pre-existing cardiovascular disease: a series of cases during the fourth epidemiologic wave in Mexico City].

Celso A Mendoza-González, Neftalí E Antonio-Villa, Mireya B Contreras-Alanis, María F Fernández-Sandoval, Jimena Castillo-Macías, Daniel E Sandoval-Colin, Jacobo S Vera-Chávez, Víctor A Quiroz-Martínez, Karina Del Valle-Zamora

Abstract readEnglish Abstract
In one paragraph

Article in Archivos de cardiologia de Mexico, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Celso A Mendoza-GonzálezCardiología Adultos, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Neftalí E Antonio-VillaCardiología Adultos, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Mireya B Contreras-AlanisCardiología Adultos, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
María F Fernández-SandovalCardiología Adultos, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Jimena Castillo-MacíasCardiología Adultos, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Daniel E Sandoval-ColinCardiología Adultos, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Jacobo S Vera-ChávezCardiología Adultos, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Víctor A Quiroz-MartínezCardiología Adultos, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.
Karina Del Valle-ZamoraCardiología Adultos, Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, México.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: SARS-CoV-2 infection induces an immune response that causes excessive inflammation damaging cardiac tissue and vascular endothelium. The objective of this study is to review a series of cases of hospitalized patients with pre-existing cardiac disease to describe the clinical behavior and highlight the low frequency of morbidity and mortality. Method: Retrospective study of 17 patients with a confirmed diagnosis of COVID-19 by polymerase chain reaction test or antigen test, a history of cardiovascular disease with or without comorbidities, and a history of at least one dose of the vaccine for COVID-19, during the period between December 30, 2021 and March 17, 2022 at the Ignacio Chávez National Institute of Cardiology in Mexico City. Results: The most frequent cardiac pathology was acute myocardial infarction (31.25%) and the most common arrhythmia was atrial fibrillation (25%). The median number of days of hospital stay was 10 days (interquartile range: 4-14). Regarding the outcomes, 94% of the patients were discharged due to clinical improvement, and only one patient died during his hospitalization. Conclusions: It is crucial to continue investigating SARS-CoV-2 effects in patients pre-existing heart disease and in those with persistent symptoms after infection. This will allow the development of more effective strategies for the treatment and prevention of cardiovascular complications associated with COVID-19.

Indexed as

Cardiovascular DiseasesCOVID-19AgedAged, 80 and overFemaleHospitalizationHumansLength of StayMaleMexicoMiddle AgedRetrospective StudiesAcute myocardial infarctionCOVID-19MyocarditisPericarditis

Identifiers

PMID39058955
PMCPMC12148541

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.